Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and ... The drugmaker’s stock LLY rose 0.5% in regular trading on Thursday after the company said it ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

With social media's history of hyped-up health trends, does a 'Mounjaro drink' drink deliver results - or is it just another internet myth? From 'sleepy girl cocktails' to 'oatzempic' drinks there ...

EGOT winner Whoopi Goldberg railed against an ad that's circulating on social media with a manipulated version of her ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue ... The drugmaker's stock (LLY) rose 0.5% in regular trading on Thursday after the company said it expects to generate an adjusted 2025 ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...